Pregnancy and Fibrinogen Disorders
- Conditions
- Hypofibrinogenemia, CongenitalAfibrinogenemia, CongenitalDysfibrinogenemia, Congenital
- Registration Number
- NCT03920332
- Lead Sponsor
- University Hospital, Geneva
- Brief Summary
The aim of this observational study is to evaluate the prevalence of uncomplicated pregnancies in women suffering from congenital fibrinogen disorders (i.e, hypofibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia) as well as to describe pregnancies outcomes in such diseases.
- Detailed Description
Women with quantitative or qualitative fibrinogen disorders are often more prone to obstetrical complications, from bleeding to recurrent miscarriages or thrombosis. Data on fibrinogen levels variations throughout the pregnancy and on the delivery management are lacking. In this observational study will be include adult women with pas obstetrical history. A general questionnaire on demographics and clinical data will be filled out by the patient's physician. A detailed questionnaire on obstetrical data will also be completed contacting the patient in case of lacking data.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 149
- Inherited fibrinogen disorders (hypofibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia)
- At lest one past pregnancy
- Adult
- No past pregnancy
- Not confirmed fibrinogen disorder
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of normal issue pregnancy At inclusion All pregnancy not resulting in miscarriage, stillbirth or abortion
- Secondary Outcome Measures
Name Time Method Modalities of delivery At inclusion Instrumental delivery vs none
Prevalence of pregnancy without complications At inclusion All pregnancy not resulting in intrauterine growth retardation, preterm labor, pregnancy-induced hypertension, gestational diabetes, preeclampsia, abruption placenta, anamniota, vaginal bleeding requiring medical intervention
Post-partum complications At inclusion Post-partum haemorrhage and/or thrombotic event within 3 months after the delivery
Fibrinogen variations At inclusion Fibrinogen levels throughout the pregnancy
Trial Locations
- Locations (3)
Hopital Port-Royal
🇫🇷Paris, France
Jessenius Faculty of Medicine and University Hospital
🇸🇰Martin, Slovakia
University Hospitals of Geneva
🇨ðŸ‡Geneva, Switzerland